Frontage Laboratories Executive and Leadership Team

Daniella Kranjac, the Co-Chief Executive Officer at Frontage Laboratories, directs the overarching corporate strategy and business development initiatives. Focusing on the expansion of integrated drug discovery services, Kranjac aligns organizational goals with the evolving needs of biotechnology clients. This leadership role involves cultivating strategic partnerships and overseeing the commercial trajectory of the firm. By identifying emerging market opportunities, Daniella Kranjac ensures the company maintains a competitive edge in the CRO landscape. The Co-Chief Executive Officer also collaborates with the Board to refine long-term growth objectives. Through rigorous oversight of service delivery models, Kranjac drives operational excellence across North American and international research facilities. This executive leadership ensures that all scientific advancements translate into tangible value for pharmaceutical partners, ultimately securing the firm's position as a premier provider of comprehensive product development services.

Zhongping Lin, the Co-Chief Executive Officer at Frontage Laboratories, architects the scientific vision and technical capabilities of the organization. Overseeing the integration of drug metabolism, pharmacokinetics, and bioanalysis, Lin ensures that all laboratory operations meet stringent regulatory standards. This leadership role involves guiding the technical teams through complex preclinical and clinical trial material manufacturing processes. By fostering a culture of scientific innovation, Zhongping Lin directly impacts the success of molecule development for global clients. The Co-Chief Executive Officer also manages the alignment of research methodologies with international regulatory requirements in the United States and China. Through the continuous optimization of analytical testing and formulation development, Lin drives the efficiency of the drug development pipeline. This strategic focus enables the firm to support diverse biotechnology companies in achieving their critical development goals with precision and scientific rigor.

Huan Wang, the Interim Chief Financial Officer at Frontage Laboratories, directs the financial strategy and fiscal health of the organization. Overseeing capital allocation and budgetary planning, Wang ensures that the company maintains the necessary resources to support its extensive research and development services. This leadership role involves managing financial reporting and risk assessment to provide transparency for stakeholders. By optimizing the financial structure, Huan Wang enables the firm to invest in advanced analytical testing and formulation development technologies. The Interim Chief Financial Officer also collaborates with executive leadership to evaluate the economic impact of expansion initiatives in international markets. Through rigorous financial oversight, Wang supports the long-term sustainability of the business model. This role remains critical in maintaining the fiscal discipline required to advance complex drug development projects while delivering consistent value to biotechnology and pharmaceutical clients worldwide.

Min Wang, the Chief Operating Officer at Frontage Laboratories, manages the daily execution of integrated service delivery across all research departments. Overseeing the operational infrastructure, Wang ensures that preclinical safety and toxicology assessment workflows remain efficient and compliant. This leadership role involves coordinating resources between clinical trial material manufacturing and bioanalytical testing units to maximize throughput. By streamlining internal processes, Min Wang supports the company's mission to accelerate drug discovery timelines for pharmaceutical partners. The Chief Operating Officer also monitors performance metrics to maintain high-quality standards across global operations. Through the implementation of scalable operational frameworks, Wang facilitates seamless collaboration between cross-functional teams. This focus on operational excellence allows the firm to handle a myriad of molecules simultaneously, ensuring that every client receives consistent, high-quality support throughout the entire drug development process.